3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
PRLD Prelude Therapeutics Inc
669
$3.77
$0.21
(5.90%)
| Watchers | 669 |
| 52-Wk Low | $1.66 |
| 52-Wk High | $5.83 |
| Market Cap | $207.08M |
| Volume | 22,647.00 |
| 52-Wk High | $5.83 |
| 52-Wk Low | $1.66 |
Prelude Therapeutics (PRLD, $4.62) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024Tickeron - Stocks • 2 months ago
This indicator may be signaling that PRLD's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Share to Feed
This is a Bearish indicator signaling PRLD's price could decline from here. Traders may explore shorting the stock or put options...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
This is a Bearish indicator signaling PRLD's price could decline from here. Traders may explore shorting the stock or put options...
This indicator may be signaling that PRLD's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE...
This indicator may be signaling that PRLD's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
Prelude Therapeutics Incorporated (NASDAQ:PRLD Free Report) HC Wainwright lifted their Q1 2024 EPS estimates for shares of Prelude Therapeutics in a report issued on Tuesday, February...
HC Wainwright downgraded shares of Prelude Therapeutics (NASDAQ:PRLD Free Report) from a buy rating to a neutral rating in a research note published on Tuesday, Marketbeat.com reports. They...